FDA warning letter · #715507

EvoLife Wellness: What the FDA Letter Means for What You Pay

Activesemaglutidetirzepatide

Status

Operating

Concerns

marketing / labeling

Issued

September 2025

Response logged

Not logged

By Marla Whitfield, Pricing EditorAugust 2026

Primary source

Read the original letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolife-wellness-715507-09092025

What FDA cited

Quoted verbatim from the letter dated September 2025

Read the full letter →

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://evolifewellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1
“The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “FDA-Approved””
2
““Clinically Proven: Semaglutide is FDA-approved for chronic weight management….””
3
“Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

Process

How a warning letter proceeds

1
Letter issued
September 2025
2
15-working-day response window
FDA gives the company 15 working days to respond in writing.
3
Close-out, if issued
FDA may post one once it is satisfied the cited issues have been corrected.

Is EvoLife Wellness still operating?

evolifewellness.com returned a live client-rendered site on 2026-08-09. The served HTML is a 538-byte shell whose <head> is still the unedited generator default — title "Lovable App", description "Lovable Generated Project", author "Lovable", with the scaffold's own TODO comments left in place — so the check was made against the site's JavaScript bundle rather than the raw page. That bundle carries EvoLife branding, tirzepatide and semaglutide copy and a price ladder running $199 / $299 / $399 / $499 / $599 / $799, which is a trading storefront rather than a placeholder. Recorded as operating on that basis; a stale generator <head> is a build artefact, not evidence about the business.

What this means for what you pay

"FDA-Approved" with nothing after it is the purest version of the problem this collection is about. Every other claim here at least names something — an ingredient, a brand, a comparison you could go and check. This one is a badge, and a badge is designed to be read at a glance and not interrogated. The habit it argues for is a single question with three parts: approved for WHAT, in WHICH form, and under WHOSE application. An approval in the United States attaches to a specific product made by a specific company to a specific formulation and strength, and it is looked up by application number. It does not attach to a molecule, and it cannot be inherited by a different preparation of the same molecule. The second claim shows how the slip happens honestly: semaglutide IS approved for chronic weight management — as Wegovy, made by Novo Nordisk — and a sentence that says so is true right up until it appears on a page selling something else. That is why FDA's reply is so short. It does not dispute the science; it points out which product the approval belongs to. Nothing in this letter concerns how these products were made or what was in them, and it has not been closed out.

Has EvoLife Wellness responded?

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence EvoLife Wellness failed to respond.

Sources

FDA Warning Letter #715507

fda.gov — the original letter

EvoLife Wellness

Official site